CLINICAL TRIALS PROFILE FOR CLEOCIN T

All Clinical Trials for Cleocin T

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00503542 ↗	Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network	Completed	Agency for Healthcare Research and Quality (AHRQ)	Early Phase 1	2007-02-01	Many women present in primary care with vaginal complaints. The best way of managing these complaints is unclear. This trial will test two different methods of managing patients with vaginal complaints. This is a pilot trial.
NCT00836004 ↗	Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2003-11-01	The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference, administered as 1 x 300 mg capsule under fed conditions.
NCT00836056 ↗	Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2003-11-01	The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference), administered as 1 x 300 mg capsule under fasting conditions.
NCT01132443 ↗	W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzo	Completed	GlaxoSmithKline	Phase 1	2010-05-06	This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben. This study compared the investigational study product and 2 marketed products: - CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free - Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP) - Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF)
NCT01132443 ↗	W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzo	Completed	Stiefel, a GSK Company	Phase 1	2010-05-06	This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben. This study compared the investigational study product and 2 marketed products: - CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free - Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP) - Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF)

Clinical Trial Conditions for Cleocin T

Condition Name

Condition Name for Cleocin T
Intervention	Trials
Healthy	2
Breast Neoplasms	1
Urinary Tract Infection	1
Anti-bacterial Agents	1

Condition MeSH

Condition MeSH for Cleocin T
Intervention	Trials
Bacterial Infections	3
Infection	2
Communicable Diseases	2
Infections	2

Clinical Trial Locations for Cleocin T

Trials by Country

Trials by Country for Cleocin T
Location	Trials
United States	6
Canada	2
India	1
China	1

Trials by US State

Trials by US State for Cleocin T
Location	Trials
New York	3
Michigan	1
Illinois	1
Arkansas	1

Clinical Trial Progress for Cleocin T

Clinical Trial Phase

Clinical Trial Phase for Cleocin T
Clinical Trial Phase	Trials
Phase 4	5
Phase 1	4
N/A	1

Clinical Trial Status

Clinical Trial Status for Cleocin T
Clinical Trial Phase	Trials
Completed	7
Not yet recruiting	2
Recruiting	1

Clinical Trial Sponsors for Cleocin T

Sponsor Name

Sponsor Name for Cleocin T
Sponsor	Trials
Teva Pharmaceuticals USA	2
Plastic Surgery Educational Foundation	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for Cleocin T
Sponsor	Trials
Other	11
Industry	4
NIH	2